CERC:NSD-Cerecor Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.51

Change

-0.02 (-0.79)%

Market Cap

USD 0.23B

Volume

0.48M

Average Target Price

USD 6.67 (+165.60%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-1.40 (-0.83%)

USD66.76B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-3.78 (-1.72%)

USD56.88B 21.36 15.53
REGN Regeneron Pharmaceuticals, Inc

-16.05 (-3.17%)

USD54.26B 16.60 12.83
BNTX BioNTech SE

+7.15 (+4.42%)

USD37.72B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-0.79 (-0.47%)

USD37.13B 61.79 35.79
BGNE BeiGene, Ltd

+9.06 (+3.00%)

USD28.73B N/A N/A
SGEN Seagen Inc

-3.84 (-2.60%)

USD26.74B 43.77 35.78
RPRX Royalty Pharma plc

+0.43 (+1.01%)

USD25.97B 22.60 15.19
GMAB Genmab A/S

+0.28 (+0.77%)

USD23.74B 26.59 3.37
CVAC CureVac N.V

+1.16 (+1.03%)

USD20.99B N/A N/A

ETFs Containing CERC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.92% 46% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.92% 46% F 23% F
Trailing 12 Months  
Capital Gain -1.18% 35% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.18% 35% F 12% F
Trailing 5 Years  
Capital Gain -35.31% 41% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.31% 41% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain 94.62% 89% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 94.62% 89% B+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 228.34% 10% F 6% F
Risk Adjusted Return 41.44% 67% D+ 63% D
Market Capitalization 0.23B 39% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 141.30 8% F 10% F
Price/Book Ratio 9.23 23% F 19% F
Price / Cash Flow Ratio -5.77 42% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -282.65% 8% F 4% F
Return on Invested Capital -195.36% 8% F 4% F
Return on Assets -74.02% 6% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.37 50% F 34% F
Short Percent 2.90% 78% C+ 55% F
Beta 1.58 40% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector